MedPath

Vaginal Misoprostol Before Intrauterine Contraceptive Device Insertion

Phase 3
Completed
Conditions
Contraception
Interventions
Drug: Placebos
Registration Number
NCT03790371
Lead Sponsor
Ain Shams University
Brief Summary

the current study was conducted to assess efficacy of vaginal misoprostol before IUD insertion following previous insertion failure

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
90
Inclusion Criteria

One previous failed attempt of IUD insertion.

Exclusion Criteria
  1. Uterine fibroid distorting the cavity.
  2. Anatomical uterine abnormality with distortion of the cavity
  3. Current pelvic inflammatory disease or recently treated pelvic inflammatory disease (PID) in the last three months.
  4. Current purulent cervicitis (chlamydia or gonorrhea).
  5. Immediately after septic abortion.
  6. Uterus size less than 6 cm and more than 9 cm.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
placeboPlaceboswhile the control group received a placebo tablet in the same regimen as the study group.
misoprostol groupMisoprostolmisoprostol (misotac® sigma pharmaceutical industries) 200 mcg vaginally applied ten and four hours prior to the second attempt of IUD insertion
Primary Outcome Measures
NameTimeMethod
the success rate for IUD insertion.four hours after misoprostol dose

the success of IUD insertion after previous attempt failure

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

AinShams university maternity hospital

🇪🇬

Cairo, Abbassya, Egypt

© Copyright 2025. All Rights Reserved by MedPath